4D Molecular Therapeutics (FDMT) Competitors

$9.80 -0.65 (-6.18%)

Closing price 03:59 PM Eastern

Extended Trading

$9.82 +0.02 (+0.16%)

As of 04:06 PM Eastern

FDMT vs. INBX, GLPG, GENB, HRMY, and TSHA

Should you buy 4D Molecular Therapeutics stock or one of its competitors? MarketBeat compares 4D Molecular Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4D Molecular Therapeutics include Inhibrx Biosciences (INBX), Galapagos (GLPG), Generate Biomedicines (GENB), Harmony Biosciences (HRMY), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry.

How does 4D Molecular Therapeutics compare to Inhibrx Biosciences?

4D Molecular Therapeutics (NASDAQ:FDMT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Inhibrx Biosciences has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Inhibrx Biosciences	N/A	-269.56%	-71.94%

4D Molecular Therapeutics has a beta of 2.77, suggesting that its share price is 177% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.88, suggesting that its share price is 288% more volatile than the broader market.

In the previous week, 4D Molecular Therapeutics had 6 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 16 mentions for 4D Molecular Therapeutics and 10 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.23 beat 4D Molecular Therapeutics' score of 0.19 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inhibrx Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inhibrx Biosciences has lower revenue, but higher earnings than 4D Molecular Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	6.02	-$140.11M	-$2.57	N/A
Inhibrx Biosciences	$1.30M	1,307.33	-$140.05M	-$9.04	N/A

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

4D Molecular Therapeutics currently has a consensus target price of $29.88, indicating a potential upside of 204.72%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 28.92%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe 4D Molecular Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

4D Molecular Therapeutics beats Inhibrx Biosciences on 10 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than 4D Molecular Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.74	$363.05M	-$1.41	N/A
4D Molecular Therapeutics	$85.21M	6.02	-$140.11M	-$2.57	N/A

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 12 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 16 mentions for 4D Molecular Therapeutics and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. 4D Molecular Therapeutics' average media sentiment score of 0.19 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.14 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.50, indicating a potential upside of 32.68%. 4D Molecular Therapeutics has a consensus target price of $29.88, indicating a potential upside of 204.72%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

4D Molecular Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 10 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Generate Biomedicines has higher earnings, but lower revenue than 4D Molecular Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	65.58	N/A	N/A	N/A
4D Molecular Therapeutics	$85.21M	6.02	-$140.11M	-$2.57	N/A

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 16 mentions for 4D Molecular Therapeutics and 15 mentions for Generate Biomedicines. 4D Molecular Therapeutics' average media sentiment score of 0.19 beat Generate Biomedicines' score of -0.29 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Generate Biomedicines has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Generate Biomedicines' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Generate Biomedicines presently has a consensus target price of $25.40, suggesting a potential upside of 63.87%. 4D Molecular Therapeutics has a consensus target price of $29.88, suggesting a potential upside of 204.72%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

4D Molecular Therapeutics beats Generate Biomedicines on 7 of the 12 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Harmony Biosciences?

4D Molecular Therapeutics (NASDAQ:FDMT) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

4D Molecular Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	6.02	-$140.11M	-$2.57	N/A
Harmony Biosciences	$899.11M	1.98	$158.69M	$2.48	12.41

4D Molecular Therapeutics currently has a consensus target price of $29.88, suggesting a potential upside of 204.72%. Harmony Biosciences has a consensus target price of $40.89, suggesting a potential upside of 32.87%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 16 mentions for 4D Molecular Therapeutics and 13 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.84 beat 4D Molecular Therapeutics' score of 0.19 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Harmony Biosciences	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Harmony Biosciences has a net margin of 16.20% compared to 4D Molecular Therapeutics' net margin of -182.34%. Harmony Biosciences' return on equity of 17.19% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Harmony Biosciences	16.20%	17.19%	11.99%

Summary

Harmony Biosciences beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Taysha Gene Therapies?

4D Molecular Therapeutics (NASDAQ:FDMT) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

4D Molecular Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

Taysha Gene Therapies has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Taysha Gene Therapies has lower revenue, but higher earnings than 4D Molecular Therapeutics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	6.02	-$140.11M	-$2.57	N/A
Taysha Gene Therapies	$7.47M	242.13	-$109M	-$0.38	N/A

In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 16 mentions for 4D Molecular Therapeutics and 8 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.61 beat 4D Molecular Therapeutics' score of 0.19 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

4D Molecular Therapeutics currently has a consensus target price of $29.88, suggesting a potential upside of 204.72%. Taysha Gene Therapies has a consensus target price of $11.64, suggesting a potential upside of 84.85%. Given 4D Molecular Therapeutics' higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

4D Molecular Therapeutics beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FDMT vs. The Competition

Export

Metric	4D Molecular Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$512.55M	$3.05B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-3.81	19.10	20.87	25.61
Price / Sales	6.02	278.05	521.62	63.45
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	1.13	4.36	9.86	6.71
Net Income	-$140.11M	$72.19M	$3.55B	$333.77M
7 Day Performance	-1.27%	-0.54%	-0.26%	0.40%
1 Month Performance	1.49%	0.31%	1.39%	4.03%
1 Year Performance	213.23%	46.31%	41.07%	36.33%

4D Molecular Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FDMT 4D Molecular Therapeutics	2.3526 of 5 stars	$9.80 -6.2%	$29.88 +204.7%	+219.6%	$512.55M	$85.21M	N/A	120	Earnings Report Analyst Revision Gap Up
INBX Inhibrx Biosciences	2.697 of 5 stars	$127.95 -0.7%	$150.00 +17.2%	+945.7%	$1.88B	$1.30M	N/A	166
GLPG Galapagos	N/A	$28.48 +1.7%	$36.50 +28.2%	N/A	$1.85B	$1.11B	N/A	1,310	High Trading Volume
GENB Generate Biomedicines	N/A	$14.46 +10.0%	$23.20 +60.4%	N/A	$1.84B	$31.89M	N/A	312	Earnings Report Analyst Forecast Analyst Revision
HRMY Harmony Biosciences	4.8222 of 5 stars	$32.59 +2.4%	$42.67 +30.9%	-10.3%	$1.84B	$868.45M	12.03	200	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FDMT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. INBX, GLPG, GENB, HRMY, and TSHA

How does 4D Molecular Therapeutics compare to Inhibrx Biosciences?

Summary

How does 4D Molecular Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does 4D Molecular Therapeutics compare to Generate Biomedicines?

Summary

How does 4D Molecular Therapeutics compare to Harmony Biosciences?

Summary

How does 4D Molecular Therapeutics compare to Taysha Gene Therapies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. INBX, GLPG, GENB, HRMY, and TSHA

How does 4D Molecular Therapeutics compare to Inhibrx Biosciences?

Is FDMT or INBX more profitable?

Which has more risk & volatility, FDMT or INBX?

Does the media favor FDMT or INBX?

Which has preferable valuation and earnings, FDMT or INBX?

Do insiders and institutionals believe in FDMT or INBX?

Do analysts rate FDMT or INBX?

Summary

How does 4D Molecular Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Is LKFT or FDMT more profitable?

Which has higher valuation & earnings, LKFT or FDMT?

Do insiders and institutionals believe in LKFT or FDMT?

Does the media refer more to LKFT or FDMT?

Which has more volatility and risk, LKFT or FDMT?

Do analysts rate LKFT or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Generate Biomedicines?

Do insiders and institutionals hold more shares of GENB or FDMT?

Which has preferable earnings & valuation, GENB or FDMT?

Does the media refer more to GENB or FDMT?

Is GENB or FDMT more profitable?

Do analysts rate GENB or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Harmony Biosciences?

Which has more volatility and risk, FDMT or HRMY?

Which has better earnings and valuation, FDMT or HRMY?

Do analysts recommend FDMT or HRMY?

Does the media prefer FDMT or HRMY?

Do institutionals and insiders hold more shares of FDMT or HRMY?

Is FDMT or HRMY more profitable?

Summary

How does 4D Molecular Therapeutics compare to Taysha Gene Therapies?

Which has more volatility and risk, FDMT or TSHA?

Is FDMT or TSHA more profitable?

Which has better earnings and valuation, FDMT or TSHA?

Does the media prefer FDMT or TSHA?

Do analysts recommend FDMT or TSHA?

Do institutionals and insiders hold more shares of FDMT or TSHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools